Posts

Showing posts with the label EGFR mutant therapies

Archive

Show more

ATNM-400 Demonstrates Superior Lung Cancer Efficacy

Image
🕓 Estimated Reading Time: 5 minutes Overview Actinium Pharmaceuticals, Inc. has announced groundbreaking preclinical data for its novel therapeutic candidate, ATNM-400 lung cancer , showcasing superior anti-tumor activity compared to existing leading treatments for EGFR-mutant non-small cell lung cancer (NSCLC). The findings, presented at the prestigious AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, highlight ATNM-400's potential to redefine treatment strategies for patients with this aggressive form of cancer. The data also revealed a significant mechanistic and synergistic effect when ATNM-400 was combined with osimertinib, a widely used third-generation EGFR inhibitor, suggesting a powerful new combination therapy approach. Background & Context Lung cancer remains a leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases. A significant subset of NSCLC patie...

Popular posts from this blog

Toto Wolff Sells Mercedes F1 Stake George Kurtz Invests

ACND Approves Budget, Rates, and Infrastructure Grants

NVIDIA Earnings Impress AI Market Continues Surge

SwitchBot RGBICWW Smart LED Strip Arrives with Apple Home

WeRide Robotaxi Revenue Surges 836% Amid Global Expansion

Top Video Game Stocks to Research Right Now

Space-Based Network Market Projected to Reach $50 Billion

Cloudian Simplifies AI Data Storage Needs

Princeton Secures State Grant for First Multi-Purpose Field

Top Robot Vacuums Expert Picks for Your Home